A sweat test is the standard diagnostic procedure for cystic fibrosis (CF) that works by measuring how much chloride, a component of salt, is present in a person’s sweat. People with CF have a faulty protein in their sweat glands that prevents chloride from being reabsorbed properly, so the salt concentration in their sweat runs abnormally high. The test itself is painless, takes about half an hour, and can be performed on infants as young as two weeks old. Despite being developed over six decades ago, it remains the single most reliable way to confirm or rule out a CF diagnosis.
How the Test Is Performed
The sweat test relies on a drug called pilocarpine to make a small patch of skin produce sweat on demand. A technician places pilocarpine on the forearm or, in babies, on the leg, and delivers a mild electrical current through the skin for about five minutes. This process, called iontophoresis, drives the pilocarpine into the sweat glands, triggering them to produce sweat locally. You might feel a slight tingling or warmth during this step, but it does not hurt and leaves no marks.
Once the stimulation phase ends, the technician attaches a collection device over the same spot. Two main collection methods are used in clinical practice. The original Gibson-Cooke method, standardized in 1959, uses gauze or filter paper sealed against the skin to absorb sweat, which is later weighed and analyzed in a lab. The more modern Macroduct system uses a small plastic coil that draws sweat into a tube through capillary action. A comparison study of the two methods in a newborn screening program found that chloride levels were statistically similar between them for most patients, with both yielding a median of about 16 mmol/L in the general screening population.
Sweat collection typically runs for 30 minutes. The lab then measures how much chloride is dissolved in the collected sample. One advantage of using pilocarpine to trigger sweating, rather than exercise or heat, is that it standardizes the conditions. Exercise-induced sweat varies enormously depending on fitness level, body temperature, emotional state, and environment, while pilocarpine stimulates the glands directly and tends to produce more uniform results across individuals.
What the Numbers Mean
The result comes back as a chloride concentration in millimoles per liter (mmol/L). For anyone older than six months, the cutoffs break down into three ranges:
- Below 30 mmol/L: CF is unlikely. This is considered a normal result.
- 30 to 59 mmol/L: Intermediate, sometimes called borderline. Further testing is needed.
- 60 mmol/L or above: Consistent with a CF diagnosis.
That intermediate range has shifted over the years. The Cystic Fibrosis Foundation lowered its lower boundary from 40 down to 30 mmol/L for people older than six months, widening the window of results that warrant follow-up. The change was meant to catch milder or atypical cases that might have been dismissed under the old thresholds. For infants under six months, the interpretation is broadly similar, though clinicians tend to be cautious because very young babies can produce somewhat different readings.
Why High Sweat Chloride Happens in CF
In a healthy sweat gland, salt is initially secreted into the sweat duct at high concentrations, and then most of the chloride gets pulled back out before the sweat reaches the skin surface. The protein responsible for that reabsorption is called CFTR. In people with CF, mutations in the gene that codes for CFTR mean the protein is either absent, misshapen, or doesn’t function properly. Chloride stays trapped in the duct, and the sweat that arrives on the skin is abnormally salty. The connection between CF and salty sweat was recognized clinically long before anyone understood the molecular cause, and the elevated salt concentration has been described as nearly unique to the disease.
When and Why the Test Is Ordered
In many countries, including the United States, all newborns are screened for CF through a blood test shortly after birth. That blood test measures a substance called immunoreactive trypsinogen (IRT), which tends to be elevated in babies with CF. Some screening programs add a DNA step, checking the dried blood sample for the most common CF-causing mutations if the IRT level is high. But neither the blood IRT level nor the DNA screen alone is enough to confirm a diagnosis. A positive newborn screen is a flag, not a verdict, and the sweat test is ordered to settle the question.
The sweat test is also ordered when someone of any age shows symptoms that raise suspicion of CF, such as chronic lung infections, persistent digestive problems, poor growth, or unusually salty-tasting skin. The Cystic Fibrosis Foundation recommends that sweat testing be done at a CF Foundation-accredited care center, where trained technicians and standardized equipment reduce the risk of errors.
Challenges With Testing Very Young Infants
One frustrating reality is that the sweat test works best when a baby is big enough to produce a sufficient volume of sweat, and very small or premature infants sometimes fail to produce enough. When the collected sample is too small for reliable analysis, the result is classified as “quantity not sufficient,” or QNS. This isn’t a diagnostic result at all; it just means the test needs to be repeated.
QNS rates are highest in the youngest infants and in those born before 37 weeks of gestation. A large population-based study found that infants weighing more than about 3 kg and born at full term were several times more likely to produce an adequate sample than smaller or premature babies. Specifically, infants above roughly 3,000 grams had over five times the likelihood of avoiding a QNS result compared to their lighter peers. For parents already anxious after a positive newborn screen, being told to come back and repeat the test is stressful but not unusual, especially if the baby is small. Most guidelines recommend waiting until a baby is at least two weeks old and weighs at least 2 kg before attempting the test.
False Positives and Conditions That Mimic CF
A chloride value above 60 mmol/L is strongly suggestive of CF, but a handful of other conditions can temporarily or persistently elevate sweat chloride and produce a misleading result. A case series documented several instructive examples: a baby with undiagnosed celiac disease had an elevated sweat chloride that returned to normal after starting a gluten-free diet; a toddler with bilateral kidney problems and a chromosomal condition had high sweat chloride that normalized years later; and two boys being treated for severe constipation with a polyethylene glycol solution containing salts showed elevated results that resolved within days of stopping the medication.
These cases are uncommon, but they matter because an isolated positive sweat test, without supporting genetic or clinical evidence, should not automatically end the diagnostic conversation. Other conditions occasionally linked to elevated sweat chloride include certain hormonal disorders, severe malnutrition, and some metabolic diseases. When the clinical picture doesn’t quite fit CF, clinicians typically pursue genetic testing and sometimes repeat the sweat test after addressing the suspected alternative cause.
The Other Side of the Coin: False Negatives
Most discussions of sweat test accuracy focus on false positives, but false negatives are arguably more dangerous because they can lead a patient to be told they don’t have CF when they actually do. Certain rare CF-causing mutations produce enough residual CFTR function that the sweat gland partially compensates, keeping chloride values in the normal range. A report described two patients carrying a specific combination of CF mutations who had normal sweat chloride values yet developed bronchiectasis, progressive obstructive lung disease, and chronic Pseudomonas colonization, all hallmarks of CF.
These patients had milder forms of the disease, with normal growth and no need for pancreatic enzyme supplementation, which likely contributed to the initial diagnostic confusion. The lesson is that a normal sweat test does not categorically exclude CF, especially in someone with suggestive symptoms. Genetic testing can identify mutations that the sweat test misses.
What Happens When Results Fall in the Borderline Range
A sweat chloride between 30 and 59 mmol/L creates genuine diagnostic uncertainty. At this point, clinicians typically order a full scan of the CFTR gene to look for disease-causing mutations. In one study of patients with borderline sweat test results, 91 individuals had chloride values in the intermediate range, and clinicians ordered complete CFTR gene scanning on 66 of them to look for mutations that might clarify the diagnosis. Some of these patients turn out to carry two CF-causing mutations and receive a CF diagnosis. Others carry one mutation and one variant of uncertain significance, placing them in a gray zone sometimes called “CF screen positive, inconclusive diagnosis” or CFSPID. And some have no identifiable mutations at all, suggesting their borderline result was a statistical blip or related to another condition.
The borderline category is one area where the two main collection methods may diverge. A study comparing Gibson-Cooke and Macroduct in children with CFSPID found a statistically significant difference between the methods in this specific group, with Gibson-Cooke yielding a median of 29 mmol/L and Macroduct yielding 22.5 mmol/L. That difference matters when the clinical decision hinges on whether a value falls above or below 30. For this reason, quality guidelines stress that labs should stick to one validated method and run internal quality-control checks at concentrations around the diagnostic cutoff points before every analysis.
The Sweat Test as a Treatment Monitor
Over the past decade, sweat chloride has taken on a second life beyond diagnosis. A new generation of drugs called CFTR modulators, which help the faulty CFTR protein fold correctly or function better at the cell surface, have transformed the treatment landscape for many people with CF. When these drugs work, the CFTR protein begins doing its job more effectively, and one measurable consequence is that sweat chloride drops. This makes the sweat test a convenient, noninvasive way to gauge whether a treatment is working at the molecular level.
Clinical trial data established sweat chloride as a useful biomarker of CFTR activity in multicenter drug trials. More recent research has gone a step further, showing that drug concentrations in the blood are directly associated with changes in sweat chloride, even after adjusting for factors like age, sex, and pre-treatment sweat chloride levels. In other words, patients whose blood levels of the modulator drug are lower tend to see less improvement in their sweat chloride, providing a measurable link between how much drug is circulating and how well the protein is being corrected. This kind of monitoring can help identify patients who might benefit from dose adjustments or who may not be absorbing their medication properly.
Conductivity Testing as a Screening Alternative
Not every facility has the equipment or trained personnel to perform a full quantitative chloride analysis. In resource-limited settings, sweat conductivity, which measures the overall electrical charge of sweat rather than chloride specifically, has been explored as a cheaper and faster screening alternative. Conductivity values tend to run higher than chloride values for the same sample because conductivity reflects all the charged particles in sweat, not just chloride.
Two studies have evaluated how well conductivity correlates with the gold-standard chloride measurement, and both found strong agreement. One reported that a conductivity cutoff of 90 mmol/L or above identified CF with nearly perfect sensitivity and specificity. A more recent study in a lower-resource setting found that a conductivity value of 80 mmol/L or above diagnosed CF with 100 percent sensitivity and specificity, while a value of 49 mmol/L or below predicted the absence of CF with 100 percent sensitivity. Intermediate conductivity values also correlated well with intermediate chloride values.
The catch is that conductivity is generally accepted only as a screening tool, not a definitive diagnostic test. European and North American guidelines still require a chloride-specific measurement for a formal CF diagnosis. But in settings where chloridometry equipment is unavailable or prohibitively expensive, conductivity can serve as a reliable first pass to decide who needs a full workup.
Quality Control and Why Testing Location Matters
The sweat test is technically simple in concept but surprisingly easy to get wrong in practice. Errors in sweat collection, sample evaporation, contamination, and lab calibration can all skew results. European CF Society guidelines specify that labs must run internal quality-control checks at multiple concentration levels, including values near the diagnostic decision points, before analyzing any patient sample. The target concentrations mirror the diagnostic cutoffs: one control below 30 mmol/L, one between 30 and 59, and one at or above 60.
The emphasis on accredited care centers comes from hard-won experience. Smaller labs that perform sweat tests infrequently are more prone to errors, and a falsely normal result in a baby with CF can delay diagnosis by months or years. The Cystic Fibrosis Foundation maintains a list of accredited centers in the United States, and equivalent organizations exist in other countries. If you or your child needs a sweat test, asking whether the facility is accredited and how often they perform the test is a reasonable and encouraged question.
Wearable Devices and the Future of Sweat Monitoring
The standard sweat test requires a trip to a clinical lab, trained personnel, and specialized equipment. Researchers are working on wearable alternatives that could change how sweat chloride is measured, particularly for ongoing treatment monitoring rather than initial diagnosis. A skin-mounted microfluidic device, sometimes called a “sweat sticker” or CF Patch, adheres to the skin and collects sweat into tiny channels. A smartphone camera then photographs a color-changing reagent inside the device, and an image-processing algorithm calculates the chloride concentration.
Early clinical studies have tested these patches using both pilocarpine-induced and exercise-induced sweat. The device showed strong correlations with chloridometry in laboratory settings for both types of sweat induction. One research group demonstrated that their device could measure serial sweat chloride concentrations remotely, raising the possibility that people with CF could track their treatment response from home instead of traveling to a clinic. The researchers were careful to note, however, that the wearable device should not replace pilocarpine-based chloridometry for making an initial CF diagnosis. The technology is aimed at monitoring, not diagnosis, at least for now.
The appeal is obvious. People with CF already manage a heavy treatment burden, and reducing the number of clinic visits needed for routine monitoring would be a real quality-of-life improvement. If ongoing trials confirm that home-based sweat monitoring reliably reflects CFTR modulator effectiveness, these wearable devices could become a standard part of CF care within the next several years.